Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2027

Published by Data Bridge Market Research Private Limited Product code 953496
Published Content info 270 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2027
Published: July 1, 2020 Content info: 270 Pages
Description

Global syndromic multiplex diagnostic market is projected to register a CAGR of 7.5% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027

Market Segmentation:

Global Syndromic Multiplex Diagnostic Market, By Products and Services (Reagents & Consumables, Instruments & Accessories, Software & Services), Infection Type (Viral, Bacterial, Parasites, Fungal and Others), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Hepatitis, Tropical Fever, Meningitis, Childhood Infections, Immunosuppression and Eye Infections), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel and Others), End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Research Institutes, Physician Office Lab's and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Rest of South America, South Africa and Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the global syndromic multiplex diagnostic market are:

Growing adoption of molecular diagnostics

Increasing regulatory approval for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) testing

Market Players:

The key market players for global syndromic multiplex diagnostic market are listed below:

GenMark Diagnostics, Inc.

QuantuMDx Group Ltd.

Nanomix, Inc.

BioFire Diagnostics (a subsidiary of bioMerieux SA)

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

QIAGEN

Hologic, Inc.

F. Hoffmann-La Roche Ltd

BD

Danaher

Prominex

Curetis

Applied BioCode, Inc.

Abbott

DiaSorin S.p.A.

Bosch Healthcare Solutions GmbH (a subsidiary of Robert Bosch GmbH)

Biocartis

Luminex Corporation

Seegene Inc.

Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION 27

  • 1.1 OBJECTIVES OF THE STUDY 27
  • 1.2 MARKET DEFINITION 27
  • 1.3 OVERVIEW OF GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 28
  • 1.4 LIMITATIONS 29
  • 1.5 MARKETS COVERED 29

2 MARKET SEGMENTATION 32

  • 2.1 MARKETS COVERED 32
  • 2.2 GEOGRAPHICAL SCOPE 33
  • 2.3 YEARS CONSIDERED FOR THE STUDY 34
  • 2.4 CURRENCY AND PRICING 34
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
  • 2.6 MULTIVARIATE MODELLING 38
  • 2.7 PRODUCTS AND SERVICES LIFELINE CURVE 38
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
  • 2.9 DBMR MARKET POSITION GRID 40
  • 2.10 VENDOR SHARE ANALYSIS 41
  • 2.11 SECONDARY SOURCES 42
  • 2.12 ASSUMPTIONS 42

3 EXECUTIVE SUMMARY 43

4 PREMIUM INSIGHTS 45

5 MARKET OVERVIEW 48

  • 5.1 DRIVERS 50
    • 5.1.1 GROWING PREVALENCE OF INFECTION DISEASES 50
    • 5.1.2 GROWING ADOPTION OF MOLECULAR DIAGNOSTICS 54
    • 5.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 55
    • 5.1.4 INCREASING DEMAND FOR ACCURATE AND FAST DIAGNOSTIC RESULTS 56
    • 5.1.5 IMPROVING DIAGNOSIS SEEKING RATE 56
  • 5.2 RESTRAINTS 57
    • 5.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 57
    • 5.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 57
  • 5.3 OPPORTUNITIES 58
    • 5.3.1 INCREASING DIAGNOSTIC HEALTHCARE EXPENDITURE 58
    • 5.3.2 INTRODUCTION OF TECHNOLOGICALLY ADVANCED PRODUCTS 59
  • 5.4 CHALLENGES 60
    • 5.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF DIAGNOSTIC PRODUCTS 60
    • 5.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 61

6 IMPACT OF COVID-19 ON GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 62

  • 6.1 IMPACT ANALYSIS ON DEMAND 62
  • 6.2 CONCLUSION 63

7 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES 64

  • 7.1 OVERVIEW 65
  • 7.2 REAGENTS & CONSUMABLES 68
  • 7.3 INSTRUMENTS & ACCESSORIES 68
  • 7.4 SOFTWARE & SERVICES 69

8 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 70

  • 8.1 OVERVIEW 71
  • 8.2 VIRAL 74
    • 8.2.1 RHINOVIRUS 75
    • 8.2.2 ROTAVIRUS 75
    • 8.2.3 ADENOVIRUS 75
    • 8.2.4 CORONAVIRUS 75
    • 8.2.5 OTHERS 75
  • 8.3 BACTERIAL 75
    • 8.3.1 PNEUMONIAE 76
    • 8.3.2 BORDETELLA PERTUSSIS 76
    • 8.3.3 STAPHYLOCOCCUS 76
    • 8.3.4 OF OTHERS 76
  • 8.4 PARASITES 77
  • 8.5 FUNGAL 77
  • 8.6 OTHERS 78

9 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 79

  • 9.1 OVERVIEW 80
  • 9.2 RESPIRATORY INFECTIONS 84
  • 9.3 GASTROENTERITIS 84
  • 9.4 SEXUALLY TRANSMITTED INFECTIONS 85
  • 9.5 HEPATITIS 86
  • 9.6 TROPICAL FEVER 86
  • 9.7 MENINGITIS 87
  • 9.8 CHILDHOOD INFECTIONS 88
  • 9.9 IMMUNOSUPPRESSION 88
  • 9.10 EYE INFECTIONS 89

10 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 90

  • 10.1 OVERVIEW 91
  • 10.2 RESPIRATORY PANEL 94
  • 10.3 GI-ENTERIC PANEL 94
  • 10.4 SEXUALLY TRANSMITTED DISEASE PANEL 95
  • 10.5 BLOOD-SEPSIS PANEL 96
  • 10.6 MENINGITIS PANEL 96
  • 10.7 OTHERS 97

11 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 98

  • 11.1 OVERVIEW 99
  • 11.2 HOSPITALS 102
  • 11.3 CLINICAL LABORATORIES 102
  • 11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 103
  • 11.5 RESEARCH INSTITUTES 103
  • 11.6 PHYSICIAN OFFICE LAB'S 104
  • 11.7 OTHERS 105

12 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY GEOGRAPHY 106

  • 12.1 OVERVIEW 107
  • 12.2 NORTH AMERICA 112
    • 12.2.1 U.S. 118
    • 12.2.2 CANADA 121
    • 12.2.3 MEXICO ` 124
  • 12.3 EUROPE 127
    • 12.3.1 GERMANY 133
    • 12.3.2 U.K. 136
    • 12.3.3 FRANCE ` 139
    • 12.3.4 ITALY 142
    • 12.3.5 SPAIN 145
    • 12.3.6 SWITZERLAND 148
    • 12.3.7 NETHERLANDS 151
    • 12.3.8 RUSSIA 154
    • 12.3.9 BELGIUM 157
    • 12.3.10 TURKEY 160
    • 12.3.11 REST OF EUROPE 163
  • 12.4 ASIA-PACIFIC 164
    • 12.4.1 CHINA 170
    • 12.4.2 JAPAN 173
    • 12.4.3 INDIA ` 176
    • 12.4.4 SOUTH KOREA 179
    • 12.4.5 AUSTRALIA 182
    • 12.4.6 SINGAPORE 185
    • 12.4.7 THAILAND 188
    • 12.4.8 MALAYSIA 191
    • 12.4.9 INDONESIA 194
    • 12.4.10 PHILIPPINES 197
    • 12.4.11 REST OF ASIA-PACIFIC 200
  • 12.5 SOUTH AMERICA 201
    • 12.5.1 BRAZIL 207
    • 12.5.2 REST OF SOUTH AMERICA 210
  • 12.6 MIDDLE EAST AND AFRICA 211
    • 12.6.1 SOUTH AFRICA 217
    • 12.6.2 REST OF MIDDLE EAST AND AFRICA 220

13 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, COMPANY LANDSCAPE 221

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 221
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 222
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE 223
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 224

14 SWOT ANALYSIS 225

15 COMPANY PROFILE 226

  • 15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMERIEUX SA) 226
    • 15.1.1 COMPANY SNAPSHOT 226
    • 15.1.2 REVENUE ANALYSIS 226
    • 15.1.3 COMPANY SHARE ANALYSIS 227
    • 15.1.4 PRODUCT PORTFOLIO 227
    • 15.1.5 RECENT DEVELOPMENTS 228
  • 15.2 SIEMENS HEALTHCARE GMBH 229
    • 15.2.1 COMPANY SNAPSHOT 229
    • 15.2.2 REVENUE ANALYSIS 229
    • 15.2.3 COMPANY SHARE ANALYSIS 230
    • 15.2.4 PRODUCT PORTFOLIO 230
    • 15.2.5 RECENT DEVELOPMENTS 230
  • 15.3 F. HOFFMANN-LA ROCHE LTD 231
    • 15.3.1 COMPANY SNAPSHOT 231
    • 15.3.2 REVENUE ANALYSIS 231
    • 15.3.3 COMPANY SHARE ANALYSIS 232
    • 15.3.4 PRODUCT PORTFOLIO 232
    • 15.3.5 RECENT DEVELOPMENT 232
  • 15.4 THERMO FISHER SCIENTIFIC INC. 233
    • 15.4.1 COMPANY SNAPSHOT 233
    • 15.4.2 REVENUE ANALYSIS 233
    • 15.4.3 COMPANY SHARE ANALYSIS 234
    • 15.4.4 PRODUCT PORTFOLIO 234
    • 15.4.5 RECENT DEVELOPMENT 234
  • 15.5 BD 235
    • 15.5.1 COMPANY SNAPSHOT 235
    • 15.5.2 REVENUE ANALYSIS 235
    • 15.5.3 COMPANY SHARE ANALYSIS 236
    • 15.5.4 PRODUCT PORTFOLIO 236
    • 15.5.5 RECENT DEVELOPMENTS 236
  • 15.6 SEEGENE INC. 237
    • 15.6.1 COMPANY SNAPSHOT 237
    • 15.6.2 REVENUE ANALYSIS 237
    • 15.6.3 PRODUCT PORTFOLIO 238
    • 15.6.4 RECENT DEVELOPMENTS 240
  • 15.7 ABBOTT 241
    • 15.7.1 COMPANY SNAPSHOT 241
    • 15.7.2 REVENUE ANALYSIS 241
    • 15.7.3 PRODUCT PORTFOLIO 242
    • 15.7.4 RECENT DEVELOPMENT 242
  • 15.8 APPLIED BIOCODE, INC. 243
    • 15.8.1 COMPANY SNAPSHOT 243
    • 15.8.2 PRODUCT PORTFOLIO 243
    • 15.8.3 RECENT DEVELOPMENTS 244
  • 15.9 BIOCARTIS 245
    • 15.9.1 COMPANY SNAPSHOT 245
    • 15.9.2 REVENUE ANALYSIS 245
    • 15.9.3 PRODUCT PORTFOLIO 246
    • 15.9.4 RECENT DEVELOPMENT 246
  • 15.10 BIO-RAD LABORATORIES, INC. 247
    • 15.10.1 COMPANY SNAPSHOT 247
    • 15.10.2 REVENUE ANALYSIS 247
    • 15.10.3 PRODUCT PORTFOLIO 248
    • 15.10.4 RECENT DEVELOPMENT 248
  • 15.11 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 249
    • 15.11.1 COMPANY SNAPSHOT 249
    • 15.11.2 REVENUE ANALYSIS 249
    • 15.11.3 PRODUCT PORTFOLIO 250
    • 15.11.4 RECENT DEVELOPMENT 250
  • 15.12 CURETIS 251
    • 15.12.1 COMPANY SNAPSHOT 251
    • 15.12.2 PRODUCT PORTFOLIO 251
    • 15.12.3 RECENT DEVELOPMENT 251
  • 15.13 DANAHER 252
    • 15.13.1 COMPANY SNAPSHOT 252
    • 15.13.2 REVENUE ANALYSIS 252
    • 15.13.3 PRODUCT PORTFOLIO 253
    • 15.13.4 RECENT DEVELOPMENT 253
  • 15.14 DIASORIN S.P.A. 254
    • 15.14.1 COMPANY SNAPSHOT 254
    • 15.14.2 REVENUE ANALYSIS 254
    • 15.14.3 PRODUCT PORTFOLIO 255
    • 15.14.4 RECENT DEVELOPMENTS 255
  • 15.15 GENMARK DIAGNOSTICS, INC. 256
    • 15.15.1 COMPANY SNAPSHOT 256
    • 15.15.2 REVENUE ANALYSIS 256
    • 15.15.3 PRODUCT PORTFOLIO 257
    • 15.15.4 RECENT DEVELOPMENTS 257
  • 15.16 HOLOGIC, INC. 258
    • 15.16.1 COMPANY SNAPSHOT 258
    • 15.16.2 REVENUE ANALYSIS 258
    • 15.16.3 PRODUCT PORTFOLIO 259
    • 15.16.4 RECENT DEVELOPMENTS 259
  • 15.17 LUMINEX CORPORATION 260
    • 15.17.1 COMPANY SNAPSHOT 260
    • 15.17.2 REVENUE ANALYSIS 260
    • 15.17.3 PRODUCT PORTFOLIO 261
    • 15.17.4 RECENT DEVELOPMENT 261
  • 15.18 NANOMIX, INC. 262
    • 15.18.1 COMPANY SNAPSHOT 262
    • 15.18.2 PRODUCT PORTFOLIO 262
    • 15.18.3 RECENT DEVELOPMENTS 262
  • 15.19 PROMINEX 263
    • 15.19.1 COMPANY SNAPSHOT 263
    • 15.19.2 PRODUCT PORTFOLIO 263
    • 15.19.3 RECENT DEVELOPMENT 263
  • 15.20 QIAGEN 264
    • 15.20.1 COMPANY SNAPSHOT 264
    • 15.20.2 REVENUE ANALYSIS 264
    • 15.20.3 PRODUCT PORTFOLIO 265
    • 15.20.4 RECENT DEVELOPMENT 265
  • 15.21 QUANTUMDX GROUP LTD. 266
    • 15.21.1 COMPANY SNAPSHOT 266
    • 15.21.2 PRODUCT PORTFOLIO 266
    • 15.21.3 RECENT DEVELOPMENT 266

16 QUESTIONNAIRE 267

17 RELATED REPORTS 270

LIST OF FIGURES

  • FIGURE 1 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 32
  • FIGURE 2 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION 35
  • FIGURE 3 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS 36
  • FIGURE 4 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS 37
  • FIGURE 5 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET : COMPANY RESEARCH ANALYSIS 37
  • FIGURE 6 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 39
  • FIGURE 7 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 40
  • FIGURE 8 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 41
  • FIGURE 9 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 44
  • FIGURE 10 GROWING PREVALENCE OF INFECTION DISEASES AND GROWING ADOPTION OF MOLECULAR DIAGNOSTICS ARE EXPECTED TO DRIVE THE GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 45
  • FIGURE 11 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2020 & 2027 45
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2020 TO 2027 46
  • FIGURE 13 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR SYNDROMIC MULTIPLEX DIAGNOSTIC MANUFACTURERS IN THE FORECAST PERIOD OF 2020 TO 2027 47
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 49
  • FIGURE 15 PREVALENCE OF CHRONIC DISEASES 50
  • FIGURE 16 PERCENTAGE OF DEATHS WORLDWIDE 51
  • FIGURE 17 TOTAL CASES OF CORONAVIRUS IN NORTH AMERICA 51
  • FIGURE 18 TOTAL CASES OF CORONAVIRUS IN EUROPE 52
  • FIGURE 19 TOTAL CASES OF CORONAVIRUS IN ASIA-PACIFIC 52
  • FIGURE 20 TOTAL CASES OF CORONAVIRUS IN SOUTH AMERICA 53
  • FIGURE 21 TOTAL CASES OF CORONAVIRUS IN MIDDLE EAST AND AFRICA 53
  • FIGURE 22 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS 59
  • FIGURE 23 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2019 65
  • FIGURE 24 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2019-2027 (USD MILLION) 66
  • FIGURE 25 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, CAGR (2020-2027) 66
  • FIGURE 26 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, LIFELINE CURVE 67
  • FIGURE 27 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2019 71
  • FIGURE 28 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2019-2027 (USD MILLION) 72
  • FIGURE 29 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2020-2027) 72
  • FIGURE 30 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE 73
  • FIGURE 31 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2019 80
  • FIGURE 32 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2019-2027 (USD MILLION) 81
  • FIGURE 33 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2020-2027) 81
  • FIGURE 34 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE 82
  • FIGURE 35 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2019 91
  • FIGURE 36 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2019-2027 (USD MILLION) 92
  • FIGURE 37 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2020-2027) 92
  • FIGURE 38 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE 93
  • FIGURE 39 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2019 99
  • FIGURE 40 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2019-2027 (USD MILLION) 100
  • FIGURE 41 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2020-2027) 100
  • FIGURE 42 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 101
  • FIGURE 43 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2019) 108
  • FIGURE 44 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY REGION (2019) 109
  • FIGURE 45 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY REGION (2020 & 2027) 109
  • FIGURE 46 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY REGION (2019 & 2027) 110
  • FIGURE 47 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY TYPE (2020-2027) 110
  • FIGURE 48 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2019) 112
  • FIGURE 49 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2019) 113
  • FIGURE 50 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 113
  • FIGURE 51 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 114
  • FIGURE 52 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES (2018-2027) 114
  • FIGURE 53 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2019) 127
  • FIGURE 54 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2019) 128
  • FIGURE 55 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 128
  • FIGURE 56 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 129
  • FIGURE 57 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES (2018-2027) 129
  • FIGURE 58 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2019) 164
  • FIGURE 59 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2019) 165
  • FIGURE 60 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 165
  • FIGURE 61 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 166
  • FIGURE 62 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES (2018-2027) 166
  • FIGURE 63 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2019) 201
  • FIGURE 64 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2019) 202
  • FIGURE 65 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 202
  • FIGURE 66 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 203
  • FIGURE 67 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES (2018-2027) 203
  • FIGURE 68 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2019) 211
  • FIGURE 69 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2019) 212
  • FIGURE 70 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 212
  • FIGURE 71 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2027) 213
  • FIGURE 72 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES (2018-2027) 213
  • FIGURE 73 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2019 (%) 221
  • FIGURE 74 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2019 (%) 222
  • FIGURE 75 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2019 (%) 223
  • FIGURE 76 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2019 (%) 224
Back to Top